There are significant differences in the pharmacokinetic properties of inhaled corticosteroids currently available for use in treatment of asthma and this can result in differences in pharmacodynamic activity. All currently used inhaled corticosteroids are rapidly cleared from the body, but show varying levels of oral bioavailability, with fluticasone propionate having the lowest. Following inhalation, there is also considerable variability in the rate of absorption from the lung, and pulmonary residence times are greatest for fluticasone propionate and triamcinolone acetonide, and shortest for budesonide and flunisolide. Cortisol suppression is frequently used as a surrogate marker of systemic corticosteroid activity. Cortisol release displays a circadian rhythm, which can be mathematically modelled and the effects of exogenous corticosteroids on cortisol suppression established. However, when interpreting the effects of inhaled corticosteroids on cumulative cortisol suppression, it is important to take into consideration the pharmacokinetic properties of each particular drug, together with the study design and the time of administration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0954-6111(97)90102-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Challenges in treating patients with comorbid asthma and bronchiectasis.
Respir Med
January 2025
Department of Internal Medicine ASL Salerno, 'Santa Maria della Speranza', Hospital, Salerno, Italy; Postgraduate Program in Allergy and Clinical Immunology, University of Naples 'Federico II', Naples, Italy.
The management of patients with overlapping asthma and bronchiectasis requires a tailored approach, starting with a comprehensive assessment of the patient's clinical profile, including the severity of asthma and the extent of bronchiectasis. Inhaled corticosteroids (ICS) are often recommended, but their use should be carefully monitored because of the risk of increased infection. If the asthma is well controlled and the bronchiectasis remains stable, a gradual reduction in the dose of ICS may be considered.
View Article and Find Full Text PDFMinimising inhaled corticosteroids for COPD.
Afr J Prim Health Care Fam Med
December 2024
Department of Anaesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver.
This Therapeutic Letter considers the evidence for inhaled corticosteroids (ICS) as a treatment for Chronic Obstructive Pulmonary Disease (COPD). Drug therapy aims to alleviate symptoms, enhance functional capacity and prevent exacerbations, but has not consistently shown to reduce mortality or improve quality of life based on randomised trials.Inhaled corticosteroids have shown limited benefits for COPD symptoms and exacerbations but increased risks of serious harms.
View Article and Find Full Text PDFAtypical femoral fracture in a patient with nutritional osteomalacia: a case report and literature review.
J Surg Case Rep
January 2025
Department of Orthopedic Surgery, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
Atypical femoral fractures (AFF) are rare stress fractures with specific diagnostic criteria, as outlined in a report published by the American Society for Bone and Mineral Research. These criteria are categorized into major and minor features, and AFF can be classified as either complete or incomplete. Bisphosphonates have been shown to increase the risk of AFF, and most cases of AFF are associated with bisphosphonate use.
View Article and Find Full Text PDFEfficacy of Nebulized Budesonide and Systemic Corticosteroids During Hospitalization on All-Cause Mortality in AECOPD Patients: A Real-World Study.
Lung
January 2025
Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Background: Guidelines specify steroids as therapy for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, the duration of survival benefit associated with steroids and the optimal dosage of nebulized budesonide (NB) during hospitalization remain unclear.
Methods: We conducted a retrospective study of hospitalized AECOPD patients.
PDE4 Inhibitors and their Potential Combinations for the Treatment of Chronic Obstructive Pulmonary Disease: A Narrative Review.
Open Respir Med J
November 2024
New Drug Discovery Research, Mankind Research Centre, Mankind Pharma Limited, Plot No 191-E, Sector 4-II, IMT Manesar, Gurugram, India-122051.
Chronic Obstructive Pulmonary Disease (COPD) is associated with cough, sputum production, and a reduction in lung function, quality of life, and life expectancy. Currently, bronchodilator combinations (β2-agonists and muscarinic receptor antagonists, dual therapy) and bronchodilators combined with inhaled corticosteroids (ICS), triple therapy, are the mainstays for the management of COPD. However, the use of ICS in triple therapy has been shown to increase the risk of pneumonia in some patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!